← All trials
NCT02935192
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 28, 2016
- Primary completion
- Jan 8, 2017
- Completion date
- Mar 25, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 476
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Institute of Virology, Vaccines and Sera, TorlakLead sponsor
- Cliniical Center of SerbiaStudy chair
- World Health OrganizationCollaborator
- Comac MedicalCollaborator
- PATHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.